RESUMO
BACKGROUND: Transcatheter aortic-valve implantation (TAVI) was introduced in 2002 and the first implants in our country were performed in 2010. AIM: To review the TAVI experience in our hospital, considering the technology improvements and gained experience throughout this period. MATERIAL AND METHODS: All patients undergoing TAVI in our center were included. Results and complications were adjudicated according to the Valve Academic Research Consortium-2 (VARC-2) criteria. Patients were divided in 3 groups, according to procedural year: Period 1: 2010-2015 (n = 35); Period 2: 2016-2018 (n = 35); Period 3: 2019-2021 (n = 41). Mortality up to one year after the procedure was recorded. RESULTS: Between 2010 and 2021, 111 TAVI procedures were performed. The mean age of patients was 82 years and 47% were women. Risk scores for in-hospital mortality were STS 6.7%, EUROSCORE II 8.0% and ACC/STS TAVR Score 4.9%. The trans-femoral route was used in 88% and a balloon-expandable valve was chosen in 82% of patients. A successful implant was achieved in 96%, with an in-hospital mortality of 1.8%. Mortality at 30 days and 1-year were 2.7 and 9.0%, respectively. During period 3, 100% of implants were successful, with no in-hospital mortality, less vascular complications (p < 0.01), less stroke (p = 0.04), less severe paravalvular leak (p = 0.01) and significantly lower rate of acute complications (p < 0.01). CONCLUSIONS: TAVI achieves excellent results. With greater experience and better available technologies, these results are even more favorable.
Assuntos
Humanos , Masculino , Feminino , Idoso de 80 Anos ou mais , Estenose da Valva Aórtica/cirurgia , Próteses Valvulares Cardíacas/efeitos adversos , Substituição da Valva Aórtica Transcateter/efeitos adversos , Substituição da Valva Aórtica Transcateter/métodos , Fatores de Risco , Resultado do TratamentoRESUMO
Introducción: La microembolización se asocia a más eventos cardiovasculares adversos (MACE) especialmente en angioplastía (PTCA) de puentes venosos aortocoronarios (PAC) o en síndrome coronario agudo (SCA). El stent MGuard evitaría la embolización distal. Nuestro objetivo: evaluar el stent con micromalla de dacron como alternativa de protección embólica. Métodos: Registro prospectivo de PTCA con stent MGuard en de SCA de PAC y vasos nativos. Resultados: 15 angioplastias, de ellas 53 por ciento con infarto agudo miocárdico con supradesnivel de ST (IAM con SDST). PTCA en vasos nativos: 60 por ciento y PAC: 40 por ciento (antigüedad: 13 +/- 3 años). El 53 por ciento tuvo flujo inicial TIMI 0-1, alto contenido trombótico (66 por ciento: 4-5 en escala de trombos TIMI). Se predilató la lesión en 73 por ciento de los casos, se empleó Reopro en 2 casos, no se usó filtros de protección ni aspirador de trombos. Las dimensiones del stent MGuard: 22.2 +/- 4.4 mm de largo por 3.7 +/- 0.44 mm de diámetro. El 100 por ciento con flujo TIMI 3 final, 93 por ciento con impregnación miocárdica grado 3. Subgrupo de IAM con SDST: 71 por ciento obtuvo < 23 cuadros TIMI/segundo, 100 por ciento con regresión del SDST mayor de 50 por ciento a 90 minutos de PTCA. Subgrupo de PTCA de PAC: (excepto caso de PTCA de PAC en IAM c/SDST) no se registró elevación de la CK total o MB post PTCA. Seguimiento: un caso de trombosis al mes. Conclusión: El MGuard stent parece ser efectivo en la protección de la microcirculación. Se requieren estudios para evaluar la seguridad clínica y eficacia en protección embólica.
Background: Coronary angioplasty (PTCA) is associated to a greater incidence of major adverse cardiac events (MACE) in patients with stenosis of saphenous vein grafts (SVG) and in those with acute coronary syndromes (ACS). The MGuard stent, a device with a dacron micro mesh, is currently being evaluated for the prevention of distal thrombotic embolization in these patients. Aim to evaluate the MGuard stent, for the prevention of distal embolization. Methods: analysis of a prospective registry of patients submitted to PTCA for ACS in native coronary arteries or occluded SVG using the MGuard stent. Results: 15 PTCA procedures were performed, 53 percent in patients with ST segment elevation acute myocardial infarction (STE-MI). PTCA was performed in native vessels in 60 percent patients and in SVG in 40 percent. Interval from surgery in these patients was 13+/-3 years. 53 percent of patients had initial TIMI fow rate 0-1 and 66 percent had a thrombotic load of 4-5 (TIMI scale). Lesions were predilated in 73 percent of cases; abxicimab was used in 2 patients and no protection filters or thrombus aspiration were performed. MGuard stent dimensions were 22.2+/-4.4 mm in length, and 3.7+/-0.44 mm in diameter. Final TIMI 3 fow was observed in all patients; 93 percent of then had grade 3 myocardial impregnation. In the subgroup of patients with STE-MI, a 23 frames/sec TIMI frame count was observed with >50 percent reduction of ST elevation 90 min after PTCA. In patients with SVG, except one patient with ACS, no elevation of total or MB- CK was observed. Follow up revealed reocclusion in 1 patient, 1 month after the procedure. Conclusion: The MGuard stent appears to be an effective device to protect the microcirculation form distal embolization during PTCA. Studies with larger number of patients and extended periods of follow up are encouraged by these results.
Assuntos
Humanos , Masculino , Adulto , Feminino , Pessoa de Meia-Idade , Angioplastia Coronária com Balão/instrumentação , Embolia/prevenção & controle , Stents , Síndrome Coronariana Aguda/terapia , Angioplastia Coronária com Balão/métodos , Seguimentos , Estudos Prospectivos , Próteses e ImplantesRESUMO
Introducción: Uno de los mecanismos que explicaría la variabilidad en la agregación plaquetaria observada en la respuesta inhibitoria a clopidogrel es el polimorfismo del receptor P2Y12 de ADP plaquetario, específicamente, el haplotipo H2 y H1/H2. No se ha descrito la prevalencia del haplotipo H1/H2 del receptor plaquetario en pacientes con enfermedad coronaria. Objetivo: Evaluar la presencia del haplotipo H1/H2 del receptor P2Y12 en un grupo de pacientes con enfermedad coronaria Métodos: Estudio prospectivo en pacientes sometidos en forma electiva a angioplastía coronaria con stent. Todos recibieron aspirina y una dosis de carga de clopidogrel de 600 mg, seguido de dosis de mantención de 75 mg/día. En todos se midió agregación plaquetaria previo a la dosis de carga de clopidogrel (día 0) y luego entre 6º y 8º día det ratamiento. La agregación plaquetaria se expresó de acuerdo al porcentaje de cambio respecto del valor basal. Se utilizó test t student pareado para evaluar el porcentaje de cambio. Se amplificó el segmento de interés del ADN de los pacientes mediante PCR y se determinó la presencia del haplotipo H1/H2 usando enzimas de restricción. Resultados: Se enrolaron 40 pacientes, 34 (85 por ciento) hombres, edad promedio 61 +/-12 años. El promedio de agregación plaquetaria, previo y durante terapia con clopidogrel fue de 64 +/-10 por ciento y 41 +/-14 por ciento, respectivamente (p<0.0001) frente a ADP 8 µM. La respuesta de agregación a clopidogrel presentó una distribución normal según el test de Kolmogorov-Smirnov (p=0.58). Los pacientes se estratificaron de acuerdo al porcentaje de cambio en cuartiles y el cuartil de menor cambio representó una diferencia menor a 10 por ciento. De estos pacientes, 30 por ciento (3 pacientes) tenían el haplotipo H1/H2. En total, se demostró la presencia del haplotipo H1/H2 en 4 (10 por ciento) pacientes...
Background: One factor influencing the variability in the anti aggregation effect of clopidogrel is the polymorphism of the platelet P2Y12 ADP receptor, specifically the H2 and H1/H2 haplotypes. The prevalence of the H1/H2 haplotype has not been described in patients with coronary artery disease. Aim: To evaluate the presence of H1/H2 haplotype of P2Y12 receptor in patients with coronary artery disease. Methods: A prospective study was conducted in patients undergoing elective PTCA with stenting. All received aspirin followed by a loading dose of clopidogrel 600 mg and a maintenance dose of 75 mg daily. Platelet aggregation was measured prior to the loading clopidogrel dose and at 6 and 8 days post treatment. Platelet aggregation was indicated as the percent change over the basal value. The Students t test was used to evaluate the response. The DNA segment involved was amplified by PCR and the H1/H2 haplotype was determined using restriction enzymes. Results: Fourty patients (85 percent males) with mean age 61 years (SD 12) were studied. Mean platelet aggregation changed from a basal value of 64+/-10 to a post clopidogrel value of 41 +/-14 percent (p<0.0001) with an ADP level of 8 µM. The platelet aggregation response was normal according to Kolmogorov-Smirnov. The lowest quartile of platelet aggregation showed a <10 percent change. Three patients in this group (30 percent) had the H1/H2 haplotype. The overall incidence of this haplotype was 10 percent (4 patients). Conclusion: Clopidogrel does not induce a significant decreased platelet aggregation in 25 percent of patients subjected to coronary angioplasty. A third of this patients exhibited the H1/H2 haplotype for the P2Y12 receptor. This group of patients might be at increased risk from subsequent cardiovascular events.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Agregação Plaquetária , Doença das Coronárias/genética , Doença das Coronárias/metabolismo , Agregação Plaquetária/genética , Variação Genética , Haplótipos , Inibidores da Agregação Plaquetária/farmacologia , Reação em Cadeia da Polimerase , Polimorfismo Genético , Estudos Prospectivos , /análise , /genética , Ticlopidina/antagonistas & inibidores , Ticlopidina/farmacologiaRESUMO
Introducción : Se ha sostenido que el tratamiento de elección del infarto agudo al miocardio (IAM) sería la Angioplastía Primaria (AP). Para optimizar el resultado de la AP, esta debe ser efectuada sin demoras. En nuestro país existe escasa información acerca del cumplimiento de las recomendaciones internacionales al respecto. Objetivo: Estudiar los tiempos transcurridos entre el inicio del dolor hasta la realización de la AP, y evaluar si existen o no diferencias respecto al horario en que ocurrió el evento. Método: Estudio retrospectivo de los pacientes (pac) con IAM sometidos a una AP desde enero de 2002 a junio de 2003 en nuestro centro. Los horarios de la AP fueron definidos como hábil (HA), nocturno (HN) y festivo (HF). Los resultados se expresan como promedio ± DS y las comparaciones entre los grupo se efectuaron con ANOVA. Resultados: Se analizaron 103 pac, edad 59± 12 años, 78 por ciento hombres.